Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223008 · ClinicalTrials.gov registry record · NA
Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine
A NA study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT07223008: Recruiting NA study, sponsored by Johns Hopkins University.
NCT07223008 is a NA study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223008, a NA study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Interventions
- DEVICE embolization of middle meningeal arteries
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2026-04-24 |
| Est. Completion | 2028-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223008
The ClinicalTrials.gov registry entry for NCT07223008 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which embolization of middle meningeal arteries is the first listed.
NCT07223008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07223008 about?
NCT07223008 is a clinical study titled "Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine". This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used i...
What is the current status of trial NCT07223008?
This trial is currently recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2026-04-24. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07223008?
The interventions under investigation include: embolization of middle meningeal arteries (DEVICE).
Who is sponsoring clinical trial NCT07223008?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.